Minnesota is currently home to 2063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393
Recruiting
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Gender:
ALL
Ages:
All
Trial Updated:
02/11/2025
Locations: Clinical Trial Site, Rochester, Minnesota
Conditions: Primary Hyperoxaluria Type 1
Register for Updates
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Recruiting
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/11/2025
Locations: Clinical Trial Site, Minneapolis, Minnesota
Conditions: Acute Hepatic Porphyria
Register for Updates
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
AB-1002 in Patients With Class III Heart Failure
NCT04179643
Recruiting
This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. Patients with non-ischemic cardiomyopathy will be enrolled until up to 17 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Minneapolis Heart Foundation Institute, Minneapolis, Minnesota
Conditions: Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure，Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
Register for Updates
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
NCT03901807
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Septic Shock, Endotoxemia
Register for Updates
HeartBeet Clinic Pilot Trial
NCT06486532
Recruiting
The goal of the current study is to conduct a pilot randomized controlled trial comparing the HeartBeet Clinic, a 16-week lifestyle medicine program with virtual, small-group coaching, to a self-paced, online education program. In this pilot study, the primary goals will be to assess acceptability and feasibility of the study and intervention procedures to prepare for a larger efficacy trial.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/10/2025
Locations: Park Nicollet Cardiology, Saint Louis Park, Minnesota
Conditions: Hyperlipidemia, Hypertension
Register for Updates
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
NCT06271512
Recruiting
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Gender:
ALL
Ages:
All
Trial Updated:
02/10/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Beta-Thalassemia
Register for Updates
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Recruiting
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed s... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/10/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study of BION-1301 in Adults With IgA Nephropathy
NCT05852938
Recruiting
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Intermed Consultants, Edina, Minnesota
Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Register for Updates
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347
Recruiting
The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follow-up time points to assess the primary endpoint.
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/10/2025
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Register for Updates